{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T12:52:25Z","timestamp":1787403145023,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10384-026-01356-x","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:00:53Z","timestamp":1779166853000},"page":"867-875","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["One-year outcomes of treat-and-extend regimen with intravitreal aflibercept 8 mg for treatment-na\u00efve neovascular age-related macular degeneration"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2311-0280","authenticated-orcid":false,"given":"Hidetaka","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Numaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Asatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"1356_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2023.26074","volume":"331","author":"M Fleckenstein","year":"2024","unstructured":"Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-related macular degeneration: a review. JAMA. 2024;331:147\u201357.","journal-title":"JAMA"},{"key":"1356_CR2","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0039-6257(05)80092-X","volume":"39","author":"AC Bird","year":"1995","unstructured":"Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv Ophthalmol. 1995;39:367\u201374.","journal-title":"Surv Ophthalmol"},{"key":"1356_CR3","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","volume":"402","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023;402:1449\u201358.","journal-title":"Lancet"},{"key":"1356_CR4","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s10384-021-00869-x","volume":"65","author":"K Yamashiro","year":"2021","unstructured":"Yamashiro K, Oishi A, Hata M, Takahashi A, Tsujikawa A. Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials. Jpn J Ophthalmol. 2021;65:741\u201360.","journal-title":"Jpn J Ophthalmol"},{"key":"1356_CR5","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432\u201344.","journal-title":"N Engl J Med"},{"key":"1356_CR6","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331.","journal-title":"N Engl J Med"},{"key":"1356_CR7","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537\u201348.","journal-title":"Ophthalmology"},{"key":"1356_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72\u201384.","journal-title":"Ophthalmology"},{"key":"1356_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"1356_CR10","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403:1141\u201352.","journal-title":"Lancet"},{"key":"1356_CR11","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.oret.2017.09.002","volume":"2","author":"H Matsumoto","year":"2018","unstructured":"Matsumoto H, Morimoto M, Mimura K, Ito A, Akiyama H. Treat-and-extend regimen with aflibercept for neovascular age-related macular degeneration: efficacy and macular atrophy development. Ophthalmol Retina. 2018;2:462\u20138.","journal-title":"Ophthalmol Retina"},{"key":"1356_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10578-1","volume":"12","author":"H Matsumoto","year":"2022","unstructured":"Matsumoto H, Hoshino J, Mukai R, Nakamura K, Akiyama H. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 macular neovascularization. Sci Rep. 2022;12:8195.","journal-title":"Sci Rep"},{"key":"1356_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10384-023-01040-4","volume":"68","author":"H Matsumoto","year":"2024","unstructured":"Matsumoto H, Hoshino J, Nakamura K, Akiyama H. One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-naive neovascular age-related macular degeneration. Jpn J Ophthalmol. 2024;68:83\u201390.","journal-title":"Jpn J Ophthalmol"},{"key":"1356_CR14","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s10384-025-01229-9","volume":"69","author":"H Matsumoto","year":"2025","unstructured":"Matsumoto H, Hoshino J, Numaga S, Asatori Y, Akiyama H. Loading phase outcomes of intravitreal aflibercept 8 mg for treatment-naive neovascular age-related macular degeneration. Jpn J Ophthalmol. 2025;69:911\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"1356_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ph18030438","volume":"18","author":"S Hosoda","year":"2025","unstructured":"Hosoda S, Sakurada Y, Fukuda Y, Kotoda Y, Kikushima W, Kashiwagi K. Short-term outcomes of three consecutive monthly loading administrations of aflibercept 8 mg for treatment-naive exudative age-related macular degeneration. Pharmaceuticals (Basel). 2025;18:438.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1356_CR16","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1007\/s40123-025-01239-3","volume":"14","author":"N Bartolomeo","year":"2025","unstructured":"Bartolomeo N, Schuetz YP, Nascimbeni AC, Castro DG, Crozat B, Barry MP, et al. Early outcome analysis of intravitreal aflibercept 8 mg treatment in naive patients with neovascular age-related macular degeneration using artificial intelligence. Ophthalmol Ther. 2025;14:2819\u201329.","journal-title":"Ophthalmol Ther"},{"key":"1356_CR17","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology. 2020;127:616\u201336.","journal-title":"Ophthalmology"},{"key":"1356_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0002-9394(99)00253-6","volume":"129","author":"H Iijima","year":"2000","unstructured":"Iijima H, Iida T, Imai M, Gohdo T, Tsukahara S. Optical coherence tomography of orange-red subretinal lesions in eyes with idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol. 2000;129:21\u20136.","journal-title":"Am J Ophthalmol"},{"key":"1356_CR19","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1007\/s00417-021-05293-y","volume":"259","author":"M Ohji","year":"2021","unstructured":"Ohji M, Okada AA, Sasaki K, Moon SC, Machewitz T, Takahashi K. Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study. Graefes Arch Clin Exp Ophthalmol. 2021;259:3637\u201347.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1356_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2021.1897628","author":"A Sharma","year":"2021","unstructured":"Sharma A, Kumar N, Parachuri N, Singh S, Bandello F, Regillo CD, et al. Understanding retinal vasculitis associated with brolucizumab: complex pathophysiology or Occam\u2019s razor? Ocul Immunol Inflamm. 2021. https:\/\/doi.org\/10.1080\/09273948.2021.1897628.","journal-title":"Ocul Immunol Inflamm"},{"key":"1356_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101521","volume":"26","author":"S Kusuhara","year":"2022","unstructured":"Kusuhara S, Kim KW, Miki A, Nakamura M. Angiographic findings before and after the onset of brolucizumab-associated retinal vascular occlusion and intraocular inflammation. Am J Ophthalmol Case Rep. 2022;26:101521.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"1356_CR22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10384-024-01107-w","volume":"68","author":"H Matsumoto","year":"2024","unstructured":"Matsumoto H, Hoshino J, Numaga S, Mimura K, Asatori Y, Akiyama H. Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration. Jpn J Ophthalmol. 2024;68:531\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"1356_CR23","unstructured":"Novartis Pharma K.K. Beovu\u00ae interview form. Revised November 2025. https:\/\/www.pro.novartis.com\/jp-ja\/sites\/pro_novartis_com_jp\/files\/2025-11\/if_beo_202511.pdf. Accessed 1 Dec 2025. (in Japanese)."},{"key":"1356_CR24","unstructured":"Chugai Pharmaceutical Co., Ltd. Vabysmo\u00ae intravitreal injection interview form. Revised May 2025. https:\/\/chugai-pharm.jp\/view-pdf\/?file=\/content\/dam\/chugai\/product\/vab\/inj\/if\/doc\/vab_if.pdf. Accessed 1 Dec 2025. (in Japanese)."},{"key":"1356_CR25","unstructured":"Bayer Yakuhin, Ltd. Eylea\u00ae intravitreal injection interview form. Revised September 2025. https:\/\/pharma-navi.bayer.jp\/sites\/g\/files\/vrxlpx9646\/files\/2025-09\/EYL8_IVF_20250911.pdf. Accessed 1 Dec 2025. (in Japanese)."},{"key":"1356_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241613004","volume":"24","author":"BH Moon","year":"2023","unstructured":"Moon BH, Kim Y, Kim SY. Twenty years of anti-vascular endothelial growth factor therapeutics in neovascular age-related macular degeneration treatment. Int J Mol Sci. 2023;24:13004.","journal-title":"Int J Mol Sci"},{"key":"1356_CR27","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","volume":"128","author":"J Mones","year":"2021","unstructured":"Mones J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with Brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021;128:1050\u20139.","journal-title":"Ophthalmology"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-026-01356-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-026-01356-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-026-01356-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T05:23:06Z","timestamp":1786166586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-026-01356-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1356"],"URL":"https:\/\/doi.org\/10.1007\/s10384-026-01356-x","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H. Matsumoto, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Novartis, Chugai, Senju, Santen, Bayer), Participation on a Data Safety Monitoring Board or Advisory Board (Novartis, Chugai); J. Hoshino, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Novartis, Chugai, Senju, Leica); S. Numaga, None; Y, Asatori, None; H. Akiyama, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Novartis, Chugai, Senju, Bayer, Santen, Otsuka, AMO, Pfizer, Wakamoto, Kowa, Eisai, HOYA).","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}